Ratio Therapeutics and Macrocyclics Partner for Exclusive Radiopharmaceutical Chelator Production and Distribution

BOSTON, June 13, 2025 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a leading pharmaceutical company specializing in innovative radiopharmaceuticals for cancer treatment, has forged a significant partnership with Macrocyclics Inc. (Macrocyclics), granting them exclusive rights to manufacture and distribute Ratio's proprietary chelator, Macropa™, on a global scale.

Macropa™ is a cutting-edge bifunctional chelator specifically designed for Actinium-225 (Ac-225), renowned for its potent alpha-particle emissions utilized in targeted alpha therapy (TAT) for combating cancer. This chelator can be linked to a range of molecules, including proteins and antibodies, facilitating the creation of targeted radiopharmaceuticals for alpha radiotherapy. Macropa™ distinguishes itself by its ability to rapidly and efficiently bind Ac-225 at room temperature, ensuring both selectivity and stability. This unique feature simplifies the manufacturing process, while enhancing the stability of the compound within the body.

Bill Cupelo, Chief Business Officer of Ratio, expressed enthusiasm about the recent advancements, stating, "Our focus over the past year has been on cultivating global scientific awareness and encouraging the integration of our chelator platform within the therapeutic radiopharmaceutical community. We are thrilled to see our efforts materialize as Macropa™ becomes accessible to a wider network of collaborators. This expansion aligns with our mission to improve patient outcomes through targeted cancer therapies and diagnostics."

Founded in 1995, Macrocyclics is a Contract Development and Manufacturing Organization (CDMO) specializing in chelating agents for radiopharmaceuticals and nuclear medicine. With a broad catalog of bifunctional chelating agents, the company supports research and clinical programs worldwide. Through this agreement, researchers in academia and industry can now directly purchase Macropa™ from Macrocyclics, ensuring swift access in countries such as Japan, Canada, Australia, and across Europe.

Paul Jurek, Ph.D., CEO of Macrocyclics, expressed his excitement about the partnership, stating, "Ratio's Macropa™ is a superior chelator for Ac-225, providing a crucial advantage by enabling labeling at room temperature. This is particularly beneficial when working with proteins or vectors that may degrade under heat. We are eager to serve as the exclusive manufacturer of Macropa™ and plan to expand our catalog with various derivatives, offering them under GMP conditions for researchers engaged in clinical studies."

Macrocyclics will be showcasing their products at the 2025 SNMMI Annual Meeting in New Orleans, LA, from June 21 to June 24. Ratio will also have representatives present at the event and is planning a networking session to foster connections with current and prospective users of Macropa™.

Ratio Therapeutics Inc., headquartered in Boston, is a clinical-stage pharmaceutical company dedicated to advancing next-generation radiopharmaceuticals for solid tumors, with the aim of transforming oncology treatment paradigms. The company's innovative R&D platforms, Trillium™ and Macropa™, are designed to create precision radiopharmaceuticals for therapy and imaging, focusing on pharmacokinetic modulation to enhance drug availability and tumor targeting. Ratio is currently preparing to enter clinical trials with its first FAP-targeted radiotherapeutic.

In summary, the collaboration between Ratio Therapeutics and Macrocyclics marks a significant step in the global distribution of innovative cancer treatments, leveraging the unique properties of Macropa™ to advance radiopharmaceutical research and development.